Skandinaviska Enskilda Banken Ab (Publ) Intra Cellular Therapies, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.5 Billion
- Q3 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 278,711 shares of ITCI stock, worth $35.4 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
278,711
Previous 259,121
7.56%
Holding current value
$35.4 Million
Previous $17.7 Million
14.83%
% of portfolio
0.09%
Previous 0.09%
Shares
12 transactions
Others Institutions Holding ITCI
# of Institutions
380Shares Held
84MCall Options Held
319KPut Options Held
143K-
Vanguard Group Inc Valley Forge, PA9.63MShares$1.22 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$803 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$671 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$489 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$387 Million3.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...